ArticleMenopause (New York, N.Y.)2025
Association of migraine and vasomotor symptom severity and duration among naturally menopausal women in Nurses' Health Study II.
Article in Menopause (New York, N.Y.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveMigraine and vasomotor symptoms (VMS) are prevalent brain conditions linked to female sex hormones and negatively impact the quality of life for middle-aged women. We aimed to quantify the association between migraine phenotype and VMS severity and duration across the final menstrual period.
methodsWe analyzed data from 21,468 participants in Nurses' Health Study II, an ongoing prospective cohort study of female registered nurses aged 25-42 at baseline in 1989. We included naturally menopausal individuals who reported a final menstrual period from 2007 through 2015. We analyzed the cross-sectional association between self-reported migraine headaches (with and without self-reported clinician diagnosis) and migraine phenotype (with and without aura) and VMS in midlife using logistic regression, adjusting for demographic, lifestyle, and reproductive health factors.
resultsOverall, 64% of the cohort reported VMS in the past 4 weeks. Of those experiencing VMS, 7% reported severe VMS and 31% reported VMS lasting ≥5 years. Individuals with recent (past 2 y) migraine in midlife (29%) had 30% (21%-40%) greater odds of reporting VMS than those without migraine (68% of women vs 63%). Among women reporting VMS, recent midlife migraine (vs no recent migraine) was also associated with severe (8% vs 6%, OR = 1.53, 95% CI = 1.30-1.81) and prolonged (35% vs 30% ≥5 years; OR = 1.24, 95% CI = 1.12-1.36) VMS. Although migraine phenotype was unassociated with VMS frequency or duration, migraine with aura and self-reported clinician-diagnosed migraine were more strongly associated with severe VMS than were migraine without aura or self-reported migraine.
conclusionWhile the nature of the association remains unclear, our findings highlight the importance of risk assessment and screening for VMS among women with migraine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.